Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.95 USD | +2.64% | +5.97% | +62.41% |
May. 15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
May. 13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
Financials (USD)
Sales 2024 * | 5.84M | Sales 2025 * | 4.43M | Capitalization | 1.77B |
---|---|---|---|---|---|
Net income 2024 * | -174M | Net income 2025 * | -193M | EV / Sales 2024 * | 195 x |
Net cash position 2024 * | 638M | Net cash position 2025 * | 333M | EV / Sales 2025 * | 326 x |
P/E ratio 2024 * |
-8.35
x | P/E ratio 2025 * |
-9.76
x | Employees | 30 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 70.36% |
Latest transcript on Spyre Therapeutics, Inc.
1 day | +2.64% | ||
1 week | +5.97% | ||
1 month | +5.81% | ||
3 months | +27.37% | ||
6 months | +87.30% | ||
Current year | +62.41% |
Managers | Title | Age | Since |
---|---|---|---|
Cameron Turtle
CEO | Chief Executive Officer | 34 | 23-06-21 |
Scott Burrows
DFI | Director of Finance/CFO | 47 | 23-08-31 |
Brian Connolly
CTO | Chief Tech/Sci/R&D Officer | - | Nov. 26 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tomas Kiselak
BRD | Director/Board Member | 37 | 23-06-21 |
Jeffrey Albers
BRD | Director/Board Member | 52 | Nov. 26 |
Peter Harwin
BRD | Director/Board Member | 38 | 23-06-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 34.95 | +2.64% | 393,781 |
24-05-30 | 34.05 | +6.21% | 231,487 |
24-05-29 | 32.06 | -3.11% | 261,996 |
24-05-28 | 33.09 | +0.33% | 295,562 |
24-05-24 | 32.98 | +0.92% | 323,928 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.41% | 1.77B | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- SYRE Stock